Harnessing the potential of the PAM (PI3K/AKT/mTOR) pathway to improve outcomes for those affected by cancer.
Celcuity is a commercial-stage biotechnology company developing targeted therapies for multiple solid tumor indications. The company’s first approved product, REVTORPYK (gedatolisib), targets all Class I isoforms of PI3K and the mTOR complexes to comprehensively block the PAM pathway. The PAM pathway is an important signaling pathway involved in many cancers and has historically been challenging to target.
Our Medicine
Learn more about our FDA approved therapy including important safety information and full Prescribing Information.
Our Pipeline
Advancing a robust pipeline of targeted therapies with a focus on the PI3K/AKT/mTOR pathway – Celcuity has the potential to make a transformative difference in the treatment of breast and prostate cancers.
Our Lead Candidate
Gedatolisib potently inhibits all four Class I PI3K isoforms as well as mTORC1 and mTORC2 at low nanomolar concentrations to induce comprehensive inhibition of the PAM pathway.
Our Culture
Learn more about our mission-driven company, united by a shared commitment to bring hope to cancer patients who need it most.
